259 related articles for article (PubMed ID: 23532732)
21. EGFR-dependent downregulation of Bim in epithelial cells requires MAPK and PKC-delta activities.
Quadros MR; Connelly S; Kari C; Abrams MT; Wickstrom E; Rodeck U
Cancer Biol Ther; 2006 May; 5(5):498-504. PubMed ID: 16582597
[TBL] [Abstract][Full Text] [Related]
22. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma.
Richter-Larrea JA; Robles EF; Fresquet V; Beltran E; Rullan AJ; Agirre X; Calasanz MJ; Panizo C; Richter JA; Hernandez JM; Roman-Gomez J; Prosper F; Martinez-Climent JA
Blood; 2010 Oct; 116(14):2531-42. PubMed ID: 20570860
[TBL] [Abstract][Full Text] [Related]
23. MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma.
Kong LR; Chua KN; Sim WJ; Ng HC; Bi C; Ho J; Nga ME; Pang YH; Ong WR; Soo RA; Huynh H; Chng WJ; Thiery JP; Goh BC
Mol Cancer Ther; 2015 Jul; 14(7):1750-60. PubMed ID: 25939760
[TBL] [Abstract][Full Text] [Related]
24. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
[TBL] [Abstract][Full Text] [Related]
25. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
[TBL] [Abstract][Full Text] [Related]
26. Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.
Mazzio EA; Soliman KFA
Cancer Genomics Proteomics; 2018; 15(5):349-364. PubMed ID: 30194076
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
San José-Eneriz E; Agirre X; Jiménez-Velasco A; Cordeu L; Martín V; Arqueros V; Gárate L; Fresquet V; Cervantes F; Martínez-Climent JA; Heiniger A; Torres A; Prósper F; Roman-Gomez J
Eur J Cancer; 2009 Jul; 45(10):1877-89. PubMed ID: 19403302
[TBL] [Abstract][Full Text] [Related]
28. Oncogenic kit triggers Shp2/Erk1/2 pathway to down-regulate the pro-apoptotic protein Bim and to promote apoptosis resistance in leukemic cells.
Selimoglu-Buet D; Gallais I; Denis N; Guillouf C; Moreau-Gachelin F
PLoS One; 2012; 7(11):e49052. PubMed ID: 23145067
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.
Ramakrishnan VG; Miller KC; Macon EP; Kimlinger TK; Haug J; Kumar S; Gonsalves WI; Rajkumar SV; Kumar SK
Haematologica; 2019 Oct; 104(10):2061-2074. PubMed ID: 30846494
[TBL] [Abstract][Full Text] [Related]
30. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.
Hata AN; Rowley S; Archibald HL; Gomez-Caraballo M; Siddiqui FM; Ji F; Jung J; Light M; Lee JS; Debussche L; Sidhu S; Sadreyev RI; Watters J; Engelman JA
Oncogene; 2017 Nov; 36(47):6581-6591. PubMed ID: 28783173
[TBL] [Abstract][Full Text] [Related]
31. Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation.
Ding H; Hackbarth J; Schneider PA; Peterson KL; Meng XW; Dai H; Witzig TE; Kaufmann SH
Blood; 2011 Nov; 118(18):4872-81. PubMed ID: 21673341
[TBL] [Abstract][Full Text] [Related]
32. Jak-STAT Inhibition Mediates Romidepsin and Mechlorethamine Synergism in Cutaneous T-Cell Lymphoma.
Cortes JR; Patrone CC; Quinn SA; Gu Y; Sanchez-Martin M; Mackey A; Cooke AJ; Shih BB; Laurent AP; Trager MH; Ferrando AA; Geskin LJ; Palomero T
J Invest Dermatol; 2021 Dec; 141(12):2908-2920.e7. PubMed ID: 34089720
[TBL] [Abstract][Full Text] [Related]
33. Gefitinib-resistance is related to BIM expression in non-small cell lung cancer cell lines.
Li H; Zhou S; Li X; Wang D; Wang Y; Zhou C; Schmid-Bindert G
Cancer Biother Radiopharm; 2013 Mar; 28(2):115-23. PubMed ID: 23270470
[TBL] [Abstract][Full Text] [Related]
34. Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation.
Yamaguchi H; Chen CT; Chou CK; Pal A; Bornmann W; Hortobagyi GN; Hung MC
Oncogene; 2010 Oct; 29(41):5619-29. PubMed ID: 20676141
[TBL] [Abstract][Full Text] [Related]
35. Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma.
Kim M; Thompson LA; Wenger SD; O'Bryant CL
Ann Pharmacother; 2012 Oct; 46(10):1340-8. PubMed ID: 22968522
[TBL] [Abstract][Full Text] [Related]
36. Erythropoietin-induced phosphorylation/degradation of BIM contributes to survival of erythroid cells.
Abutin RM; Chen J; Lung TK; Lloyd JA; Sawyer ST; Harada H
Exp Hematol; 2009 Feb; 37(2):151-8. PubMed ID: 19100675
[TBL] [Abstract][Full Text] [Related]
37. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
Hall CP; Reynolds CP; Kang MH
Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
[TBL] [Abstract][Full Text] [Related]
38. Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma.
Zhao L; Okhovat JP; Hong EK; Kim YH; Wood GS
Neoplasia; 2019 Jan; 21(1):82-92. PubMed ID: 30529073
[TBL] [Abstract][Full Text] [Related]
39. Reactive Oxygen Species-Mediated Synergism of Fenretinide and Romidepsin in Preclinical Models of T-cell Lymphoid Malignancies.
Makena MR; Koneru B; Nguyen TH; Kang MH; Reynolds CP
Mol Cancer Ther; 2017 Apr; 16(4):649-661. PubMed ID: 28119491
[TBL] [Abstract][Full Text] [Related]
40. Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.
Noonan AM; Eisch RA; Liewehr DJ; Sissung TM; Venzon DJ; Flagg TP; Haigney MC; Steinberg SM; Figg WD; Piekarz RL; Bates SE
Clin Cancer Res; 2013 Jun; 19(11):3095-104. PubMed ID: 23589175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
